Department of General, Visceral and Thoracic Surgery, Klinikum Hannoversch-Muenden, Goettingen University, Germany.
Cellular and Molecular Pharmacology, Louvain Drug Research Institute, Université catholique de Louvain (UCLouvain), Brussels, Belgium.
J Antimicrob Chemother. 2021 Nov 22;76(Suppl 4):iv9-iv22. doi: 10.1093/jac/dkab351.
Bacterial skin and soft tissue infections are among the most common bacterial infections and constitute a major burden for patients and healthcare systems. Care is complicated by the variety of potential pathogens, some with resistance to previously effective antimicrobial agents, the wide spectrum of clinical presentations and the risk of progression to life-threatening forms. More-efficient care pathways are needed that can reduce hospital admissions and length of stay, while maintaining a high quality of care and adhering to antimicrobial stewardship principles. Several agents approved recently for treating acute bacterial skin and skin structure infections have characteristics that meet these requirements. We address the clinical and pharmacological characteristics of the fourth-generation fluoroquinolone delafloxacin, and the long-acting lipoglycopeptide agents dalbavancin and oritavancin.
细菌引起的皮肤和软组织感染是最常见的细菌感染之一，给患者和医疗系统带来了沉重负担。由于潜在病原体种类繁多，其中一些对以前有效的抗菌药物具有耐药性，临床表现广泛，且有进展为危及生命形式的风险，因此治疗工作变得复杂。需要建立更有效的治疗途径，既能减少住院和住院时间，又能保持高质量的护理，并坚持抗菌药物管理原则。最近批准的几种治疗急性细菌性皮肤和皮肤结构感染的药物具有符合这些要求的特征。我们将讨论第四代氟喹诺酮类药物德拉沙星、长效糖肽类药物达巴万星和奥他万星的临床和药理学特征。
